TransCode Therapeutics Statistics

Total Valuation

RNAZ has a market cap or net worth of $6.64 million. The enterprise value is -$4.73 million.

Market Cap	6.64M
Enterprise Value	-4.73M

Important Dates

The next estimated earnings date is Wednesday, August 13, 2025, after market close.

Earnings Date	Aug 13, 2025
Ex-Dividend Date	n/a

Share Statistics

RNAZ has 833,619 shares outstanding.

Current Share Class	833,619
Shares Outstanding	833,619
Shares Change (YoY)	n/a
Shares Change (QoQ)	+690.77%
Owned by Insiders (%)	0.15%
Owned by Institutions (%)	2.86%
Float	780,143

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.66
P/TBV Ratio	0.66
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.20

Current Ratio	5.20
Quick Ratio	4.74
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-902.55

Financial Efficiency

Return on equity (ROE) is -342.99% and return on invested capital (ROIC) is -127.68%.

Return on Equity (ROE)	-342.99%
Return on Assets (ROA)	-94.84%
Return on Invested Capital (ROIC)	-127.68%
Return on Capital Employed (ROCE)	-145.47%
Revenue Per Employee	n/a
Profits Per Employee	-$3.64M
Employee Count	7
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -99.13% in the last 52 weeks. The beta is 1.33, so RNAZ's price volatility has been higher than the market average.

Beta (5Y)	1.33
52-Week Price Change	-99.13%
50-Day Moving Average	8.63
200-Day Moving Average	186.60
Relative Strength Index (RSI)	49.11
Average Volume (20 Days)	32,178

Short Selling Information

The latest short interest is 91,638, so 10.99% of the outstanding shares have been sold short.

Short Interest	91,638
Short Previous Month	115,427
Short % of Shares Out	10.99%
Short % of Float	11.75%
Short Ratio (days to cover)	1.19

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-15.54M
Pretax Income	-17.06M
Net Income	-25.51M
EBITDA	-15.47M
EBIT	-15.54M
Earnings Per Share (EPS)	-$469.07

Full Income Statement

Balance Sheet

The company has $11.57 million in cash and n/a in debt, giving a net cash position of $11.57 million or $13.88 per share.

Cash & Cash Equivalents	11.57M
Total Debt	n/a
Net Cash	11.57M
Net Cash Per Share	$13.88
Equity (Book Value)	10.29M
Book Value Per Share	12.35
Working Capital	10.53M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$12.50 million and capital expenditures -$17,925, giving a free cash flow of -$12.51 million.

Operating Cash Flow	-12.50M
Capital Expenditures	-17,925
Free Cash Flow	-12.51M
FCF Per Share	-$15.01

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

RNAZ does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-372.79%
FCF Yield	-182.84%

Analyst Forecast

The average price target for RNAZ is $280.00, which is 3,413.17% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$280.00
Price Target Difference	3,413.17%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 15, 2025. It was a reverse split with a ratio of 0.0357143:1.

Last Split Date	May 15, 2025
Split Type	Reverse
Split Ratio	0.0357143:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	2